NeurAxis (NRXS)
Prescription ear-worn stimulation for functional abdominal pain and a rectal-expulsion diagnostic device.
Something off on this page? Send us feedback.
Sells IB-Stim, an ear-worn prescription nerve-stimulation device for functional abdominal pain linked to IBS and functional dyspepsia, alongside RED, a clinical rectal-expulsion diagnostic device. Revenue comes from U.S. hospital and clinic product sales, with access shaped by trained providers, insurance coverage, reimbursement, and FDA-cleared use.
Sells IB-Stim, a prescription percutaneous electrical nerve field stimulation device worn on the ear, to U.S. hospitals and clinics for functional abdominal pain associated with irritable bowel syndrome and functional dyspepsia, including related nausea. Trained providers place the disposable device in outpatient clinics, and the company earns point-in-time product revenue through a direct sales force, online channels, and clinician-facing academic societies.
Also offers RED, a self-inflating diagnostic device for clinical assessment of rectal expulsion and rectal hypersensitivity, while studying the PENFS platform in additional conditions. Commercialization rests on provider training, payer coverage and procedure reimbursement, clinical evidence, FDA-cleared indications, and third-party manufacturing for its current products.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $8.3M · Total debt $279.4K · Total assets $10.0M · Shareholders' equity $6.7M
- Revenue
- $1.9M
- Operating income
- −$2.1M
- Net income
- −$2.3M
No dividends on record.
| Institutions26 holders · as of Mar 31, 2026 | 16.25% | 2.04M shares | |
| Insiders8 holders · as of Aug 26, 2026 | 20.79% | 2.61M shares | |
| Otherremainder | 62.96% | 7.91M shares |
12.56M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Brian P. HannaschInsider | 9.11% | 1.14M | 13Gfiled Jul 2, 2025 ↗ |
Bigger Capital Fund L PInstitution | 6.02% | 755,577 | 13Gfiled May 1, 2026 ↗ |
Gil AharonInsiderdirector | 5.00% | 628,181 | Form 4filed Aug 17, 2026 ↗ |
Aigh Capital Management LLCInstitution | 3.19% | 400,000 | 13Fas of Mar 31, 2026 |
Rosalind Advisors, Inc.Institution | 2.28% | 286,138 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Bausch Health
GI drugs address adult IBS symptoms across IBS-D and IBS-C.
- Ironwood Pharmaceuticals
Linzess targets IBS-C in the same U.S. gastroenterology channel.
- AbbVie
Linzess offers a large-scale prescription option for adult IBS-C.
- electroCore
Non-invasive vagus stimulation overlaps in bioelectronic GI therapy.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| NeurAxis | $6.00 | 0.00% | $74.2M | — | — | 14.0 | +115.7% |
| Bausch Health | $6.82 | −0.07% | $2.55B | — | 1.5 | 0.2 | +11.2% |
| Ironwood Pharmaceuticals | $4.49 | +1.81% | $725.9M | 5.7 | 3.8 | 1.9 | +32.6% |
| AbbVie | $264.00 | +0.88% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| electroCore | $9.60 | +6.08% | $85.7M | — | — | 2.3 | +28.0% |
| Median | 39.7 | 3.8 | 2.1 | +19.6% |